专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050020491A1 Decorin proteoglycan inhibitor of fibrinogen blood clotting 有权
标题翻译： Decorin蛋白聚糖抑制剂的纤维蛋白原血液凝固
公开(公告)号：US20050020491A1
公开(公告)日：2005-01-27
申请号：US10898841
申请日：2004-07-26
申请人： Magnus Hook , Tracey Dugan
发明人： Magnus Hook , Tracey Dugan
IPC分类号： A61K38/17 , A61K47/48 , C07K14/47 , C07K14/705
CPC分类号： C07K14/4725 , A61K38/1709 , A61K47/61 , A61K2300/00
摘要： The present invention provides compositions and methods of inhibiting fibrin(ogen) clot formation by utilizing decorin proteoglycan as an anticoagulating and antithrombotic agent. The decorin proteoglycan comprises a decorin core protein or a fragment thereof covalently linked to a galactosaminoglycan polysaccharide. The decorin core protein acts as an anticoagulant and as a carrier for the delivery of an antithrombotic galactosaminoglycan to fibrinogen. Fibrin clotting is inhibited by the decorin proteoglycan in a concentration-dependent fashion.
摘要翻译：本发明提供了通过利用核心蛋白聚糖蛋白聚糖作为抗凝血和抗血栓形成剂来抑制纤维蛋白（ogen）凝块形成的组合物和方法。核心蛋白聚糖蛋白聚糖包含与半乳糖聚糖多糖共价连接的核心蛋白聚糖蛋白核心蛋白或其片段。核心蛋白聚糖核心蛋白质作为抗凝血剂和作为将抗血栓形成半乳糖聚糖交付给纤维蛋白原的载体。纤维蛋白凝块以浓度依赖性方式被核心蛋白聚糖蛋白聚糖抑制。

2. 发明申请

US20060258570A1 Decorin proteoglycan inhibitor of fibrinogen blood clotting 审中-公开
标题翻译： Decorin蛋白聚糖抑制剂的纤维蛋白原血液凝固
公开(公告)号：US20060258570A1
公开(公告)日：2006-11-16
申请号：US11492159
申请日：2006-07-24
申请人： Magnus Hook , Tracey Dugan
发明人： Magnus Hook , Tracey Dugan
IPC分类号： A61K38/36
CPC分类号： C07K14/4725 , A61K38/1709 , A61K47/61 , A61K2300/00
摘要： The present invention provides compositions and methods of inhibiting fibrin(ogen) clot formation by utilizing decorin proteoglycan as an anticoagulating and antithrombotic agent. The decorin proteoglycan comprises a decorin core protein or a fragment thereof covalently linked to a galactosaminoglycan polysaccharide. The decorin core protein acts as an anticoagulant and as a carrier for the delivery of an antithrombotic galactosaminoglycan to fibrinogen. Fibrin clotting is inhibited by the decorin proteoglycan in a concentration-dependent fashion.
摘要翻译：本发明提供了通过利用核心蛋白聚糖蛋白聚糖作为抗凝血和抗血栓形成剂来抑制纤维蛋白（ogen）凝块形成的组合物和方法。核心蛋白聚糖蛋白聚糖包含与半乳糖聚糖多糖共价连接的核心蛋白聚糖蛋白核心蛋白或其片段。核心蛋白聚糖核心蛋白质作为抗凝血剂和作为将抗血栓形成半乳糖聚糖交付给纤维蛋白原的载体。纤维蛋白凝块以浓度依赖性方式被核心蛋白聚糖蛋白聚糖抑制。

3. 发明授权

US08475798B2 Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein 有权
标题翻译：识别凝固酶阴性葡萄球菌蛋白的单克隆抗体
公开(公告)号：US08475798B2
公开(公告)日：2013-07-02
申请号：US11917435
申请日：2006-06-16
申请人： Joseph M. Patti , Jeff T. Hutchins , Andrea Hall , Linda Santos , Maria Bowden , Magnus Hook
发明人： Joseph M. Patti , Jeff T. Hutchins , Andrea Hall , Linda Santos , Maria Bowden , Magnus Hook
IPC分类号： A61K39/40 , A61K39/00 , A61K39/395 , G01N33/569
CPC分类号： C07K16/1271 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/92
摘要： Monoclonal antibodies which can bind to the SdrF protein of Staphylococcus epidermidis are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus epidermidis. The monoclonal antibodies of the invention are advantageous in that they can also recognize binding domains and subdomains of the S. epidermidis SdrF protein in addition to the protein itself. Suitable compositions and passive vaccines based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.
摘要翻译：提供可以结合表皮葡萄球菌的SdrF蛋白的单克隆抗体，其可用于治疗和保护葡萄球菌如表皮葡萄球菌感染。本发明的单克隆抗体是有利的，除了蛋白质本身之外，它们还可以识别表皮葡萄球菌SdrF蛋白的结合结构域和亚结构域。还提供了基于本发明的单克隆抗体的合适的组合物和被动疫苗以及它们的使用方法。

4. 发明申请

US20130035476A1 CRYSTAL STRUCTURE OF STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A IN COMPLEX WITH FIBRINOGEN DERIVED PEPTIDE AND USES THEREOF 审中-公开
公开(公告)号：US20130035476A1
公开(公告)日：2013-02-07
申请号：US13605567
申请日：2012-09-06
申请人： Magnus Hook , Ya-Ping Ko , Emanuel Smeds , Vannakambadi K. Ganesh
发明人： Magnus Hook , Ya-Ping Ko , Emanuel Smeds , Vannakambadi K. Ganesh
IPC分类号： C07K16/12
CPC分类号： C07K14/75 , A61K38/00 , A61K38/363 , C07K14/31 , C07K16/1271 , C07K16/18 , C07K16/36 , G01N33/68 , G01N2333/31 , G01N2333/75
摘要： The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineered Staphylococcus clumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating a Staphylococcus infection in an individual.

5. 发明授权

US08017133B2 Multicomponent vaccines 有权
标题翻译：多组分疫苗
公开(公告)号：US08017133B2
公开(公告)日：2011-09-13
申请号：US12710790
申请日：2010-02-23
申请人： Joseph M. Patti , Timothy J. Foster , Magnus Hook
发明人： Joseph M. Patti , Timothy J. Foster , Magnus Hook
IPC分类号： A61K39/085
CPC分类号： C07K16/1271 , A61K39/085
摘要： Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum of Staphylococcus and other bacterial strains and against proteins that are expressed at different stages of the logarithmic growth curve. In one embodiment of the invention, a composition is provided that includes a fibrinogen binding domain of a fibrinogen binding protein and a bacterial component such as a capsular polysaccharide, and both active and passive vaccines based on these components are also provided, along with methods of treating infection using these compositions and vaccines.
摘要翻译：提供了有助于预防和治疗葡萄球菌感染的多组分疫苗，其包括某些所选择的细菌结合蛋白或其片段的组合，或对那些蛋白质或片段的抗体。通过仔细选择蛋白质，片段或抗体，提供疫苗，其对广泛的葡萄球菌和其他细菌菌株和针对在对数生长曲线的不同阶段表达的蛋白质提供保护。在本发明的一个实施方案中，提供了包括纤维蛋白原结合蛋白的纤维蛋白原结合结构域和诸如荚膜多糖的细菌组分的组合物，以及基于这些组分的主动和被动疫苗以及方法使用这些组合物和疫苗治疗感染。

6. 发明申请

US20090203627A1 Specific binding sites in collagen for integrins and use thereof 有权
标题翻译：用于整联蛋白的胶原中的特异性结合位点及其用途
公开(公告)号：US20090203627A1
公开(公告)日：2009-08-13
申请号：US12383746
申请日：2009-03-26
申请人： Magnus Hook , Xuejun Xu , Jiyeun Kim
发明人： Magnus Hook , Xuejun Xu , Jiyeun Kim
IPC分类号： A61K38/08 , C12N15/63 , C12N5/10 , G01N33/566 , C07K7/06 , C07K19/00 , C12N5/06
CPC分类号： C07K14/00 , C07K7/06 , C07K14/78 , G01N33/566 , G01N33/6887 , G01N2333/70546 , G01N2333/78 , G01N2500/02
摘要： The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods to identify specific integrin inhibitors, sequences of these inhibitors and their use in inhibiting pathophysiological conditions that may arise due to integrin-collagen interaction.
摘要翻译：本发明鉴定了胶原结合整合蛋白I结构域中III型胶原中的高亲和力结合序列。本文提供了用于表征序列的方法，包含该新型序列的肽以及肽在使细胞粘附中的用途。本文还提供了鉴定特异性整联蛋白抑制剂，这些抑制剂的序列及其在抑制由于整合素 - 胶原相互作用可能引起的病理生理学病症中的用途的方法。

7. 发明申请

US20090162379A1 Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor 审中-公开
标题翻译：金黄色葡萄球菌SdrD蛋白抑制剂附着于细胞及其用途
公开(公告)号：US20090162379A1
公开(公告)日：2009-06-25
申请号：US12286586
申请日：2008-10-01
申请人： Magnus Hook , Elena M. Barbu
发明人： Magnus Hook , Elena M. Barbu
IPC分类号： A61K39/40 , G01N33/569 , G01N33/53 , C07K14/31 , A61K38/16 , C12N5/00 , C12N1/20 , C07K16/00 , A61P31/04
CPC分类号： G01N33/5044 , A61K2039/505 , C07K16/1271 , G01N2333/31
摘要： Provided herein is a method for identifying small molecule inhibitors of S. aureus SdrD protein attachment to a host cell receptor using a structural model of SdrD protein-receptor interaction. Also provided are the small molecule inhibitors so identified and synthetic small molecules effective to bind SdrD protein and/or the host cell receptor. In addition, antibodies directed against SdrD protein are provided. Further provided are methods of treating or preventing S. aureus associated lung infections and of inhibiting S. aureus adherence to a lung cell using the small molecules and antibodies described herein.
摘要翻译：本文提供了使用SdrD蛋白 - 受体相互作用的结构模型鉴定金黄色葡萄球菌SdrD蛋白附着于宿主细胞受体的小分子抑制剂的方法。还提供了如此鉴定的小分子抑制剂和有效结合SdrD蛋白和/或宿主细胞受体的合成小分子。此外，提供了针对SdrD蛋白的抗体。还提供了使用本文所述的小分子和抗体治疗或预防金黄色葡萄球菌相关肺感染和抑制金黄色葡萄球菌粘附至肺细胞的方法。

8. 发明申请

US20070092533A1 Method of preventing T cell-mediated responses by the use of the major histocompatibility complex class II analog protein (map protein) from Staphylococcus aureus 审中-公开
标题翻译：通过使用来自金黄色葡萄球菌的主要组织相容性复合物II类模拟蛋白（图蛋白）来预防T细胞介导的应答的方法
公开(公告)号：US20070092533A1
公开(公告)日：2007-04-26
申请号：US11643714
申请日：2006-12-22
申请人： Eric Brown , Lawrence Lee , Magnus Hook
发明人： Eric Brown , Lawrence Lee , Magnus Hook
IPC分类号： A61K39/02
CPC分类号： C07K14/31 , A61K38/00
摘要： A method of immunomodulating the T cell response in Staphylococcal bacteria is provided wherein an effective amount of the Map protein from Staphylococcus aureus is administered to a host to prevent or suppress the T cell response. The present method may be utilized with either the Map protein or an effective subdomain or fragment thereof such as the Map19 protein. The present invention is advantageous in that suppression or prevention of the T cell response in a host can prevent or ameliorate a wide variety of the pathogenic conditions such as toxic shock syndrome and other diseases associated with the T cell-mediated response caused by staphylococcal infection, and is particularly useful in cases where patients have had chronic or recurrent infections from S. aureus or other staphylococcal bacteria.
摘要翻译：提供了一种在葡萄球菌中免疫调节T细胞应答的方法，其中向宿主施用有效量的来自金黄色葡萄球菌的Map蛋白以预防或抑制T细胞应答。本方法可以与Map蛋白或有效亚结构域或其片段（如Map19蛋白）一起使用。本发明的优点在于，抑制或预防宿主中的T细胞应答可以预防或改善各种各样的致病性病症如毒性休克综合征和与由葡萄球菌感染引起的T细胞介导的应答相关的其它疾病，并且在患者具有来自金黄色葡萄球菌或其它葡萄球菌的慢性或反复感染的情况下特别有用。

9. 发明申请

US20060110380A1 Compositions for inhibiting thrombin-induced coagulation and methods of use 审中-公开
标题翻译：用于抑制凝血酶诱导的凝血的组合物及其使用方法
公开(公告)号：US20060110380A1
公开(公告)日：2006-05-25
申请号：US11010406
申请日：2004-12-14
申请人： Stacey Davis , Magnus Hook
发明人： Stacey Davis , Magnus Hook
IPC分类号： A61K38/48
CPC分类号： C07K14/31 , A61K38/164 , A61K38/482 , A61K2300/00
摘要： A method of achieving safe and effective treatment or prevention of potentially harmful blood clots, or in inhibiting the coagulation of blood when so desired such as during a wide array of disease conditions including stroke, myocardial infarction, sickle-cell crisis and venous thrombosis, is provided by the administration of a fibrinogen-binding protein capable of binding at the N-terminal Bβ chain of fibrinogen, such as SdrG or Fbe, or their respective binding regions such as the A domain. In addition, compositions comprising effective amounts of the fibrinogen-binding proteins are also provided. The present anti-coagulation compositions have been shown to inhibit thrombin-induced fibrin clot formation by interfering with the release of fibrinopeptide B and the resulting anti-coagulation effects can be achieved without potential for causing or exacerbating unwanted side effects such as thrombocytopenia associated with prior art anticoagulants such as heparin.
摘要翻译：一种实现安全有效的治疗或预防潜在有害的血块，或在需要时抑制血液凝固的方法，例如在包括中风，心肌梗死，镰状细胞危象和静脉血栓形成在内的各种疾病状况下，是一种方法通过施用能够在纤维蛋白原的N-末端Bbeta链（例如SdrG或Fbe）或其各自的结合区域如A结构域结合的纤维蛋白原结合蛋白提供。此外，还提供了包含有效量的纤维蛋白原结合蛋白的组合物。已经显示本发明的抗凝组合物通过干扰纤维蛋白肽B的释放来抑制凝血酶诱导的纤维蛋白凝块形成，并且可以实现所得的抗凝血作用，而不会引起或加剧不期望的副作用，例如与先前相关的血小板减少症艺术抗凝剂如肝素。

10. 发明授权

US07045131B2 Staphylococcal immunotherapeutics via donor selection and donor stimulation 有权
公开(公告)号：US07045131B2
公开(公告)日：2006-05-16
申请号：US10091494
申请日：2002-03-07
申请人： Joseph M. Patti , Timothy J. Foster , Magnus Hook
发明人： Joseph M. Patti , Timothy J. Foster , Magnus Hook
IPC分类号： A61K39/085
CPC分类号： A61K9/0019 , A61K39/00 , A61K2039/505 , C07K16/1271 , C07K2317/20 , C07K2317/76
摘要： A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host. In either case, the donor plasma pool is preferably purified and concentrated prior to intravenous introduction into the patient, and the present invention is advantageous in that a patient can be immunized against a wide variety of potentially dangerous staphylococcal infections. Kits for identifying potential donor with high titers of the selected adhesins are also provided. The present invention thus provides methods and compositions which can be highly effective against infections associated with Staphylococcus bacteria.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式